| Identification | Back Directory | [Name]
Hetrombopag | [CAS]
2114365-78-3 | [Synonyms]
Hetrombopag
2-Furancarboxylic acid, 5-[3-[2-[4,5-dihydro-3-methyl-5-oxo-1-(5,6,7,8-tetrahydro-2-naphthalenyl)-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]- | [Molecular Formula]
C25H22N4O5 | [MOL File]
2114365-78-3.mol | [Molecular Weight]
458.47 |
| Chemical Properties | Back Directory | [Boiling point ]
745.2±60.0 °C(Predicted) | [density ]
1.47±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
3.00±0.10(Predicted) | [color ]
Brown to dark brown |
| Hazard Information | Back Directory | [Uses]
Rafutrombopag (tautomerism) is a potent thrombopoietin receptor agonist. Rafutrombopag (tautomerism) is efficacious and well tolerated with a manageable safety profile. Rafutrombopag (tautomerism) has the potential for the research of immune thrombocytopenia[1]. | [References]
[1] Mei H, et al. A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. J Hematol Oncol. 2021;14(1):37. DOI:10.1186/s13045-021-01047-9 |
|
|